Cardiology-Emergency Medicine Cardiac Biomarker Research Initiative
NCT ID: NCT01984853
Last Updated: 2015-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
575 participants
OBSERVATIONAL
2013-05-31
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The standard protocol for evaluating patients in the Emergency Department for possible acute myocardial infarction includes the measurement of cardiac troponin over 3 hours. Subjects presenting to the ED with chest discomfort or ischemic symptoms will be eligible for blood draw protocol. The study is blinded to treating physicians and does not change current standard of care. After informed consent patients will have blood samples drawn at 0, 30 minutes, 1 hour and 3 hours.
Serum from the samples will be stored in a -80 research freezer to be evaluated at a later time as new cardiac markers for acute coronary syndrome are developed.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This specimen collection study is a prospective serial draw plasma collection study designed to collect specimens for use in existing or future clinical studies. Specimen collection is expected to take approximately 30-36 months. Specimens will be collected from subjects that are being evaluated for Acute Coronary Syndrome (ACS).
Other than sample collection, no special procedures or medications are required by the study.
The study aims to enroll approximately 250-500 individuals evaluated for possible ACS in the ED.
Specimens will be obtained from the subject at the following time points:
t0 =Baseline ECG (ECG time + 60 minutes) t1= within 30 (+/- 10 minutes) minutes after t0 t2 = 1 (+/- 15 minutes) hours after t0 t3 = 3 (+/-15 minutes) hours after t0
Each sample will consist of approximately 6-8.5 ml of blood in each of two anticoagulant tube types: SST and K2EDTA plasma. Four serial specimens will be collected within 3 hours of presentation to the ED for observation of ACS.
* The Investigator or designee will obtain the subject's written informed consent prior to collecting the specimen.
* Each subject will be given a unique study number. An enrollment log will be used to document the enrollment of individuals by study number. This study number will be used to identify the individual throughout the study.
* Each subject will have a medical history reviewed and documented, as well as significant cardiac medical history documented in the subject's case report form in addition to demographic information including age, gender, race, ethnicity, and medication history.
* Each subject will have a baseline ECG obtained in the ED, vital signs and routine laboratory results. These will be documented in the subject's case report form.
* Approximately 6-8.5 ml of blood will be collected in each of two anticoagulant tube types: SST and K2EDTA plasma. The first blood collection in the ED is designated as t0 ED ECG time (+ 60 minutes). Additional blood draws of approximately 6-8.5 mL/tube type will occur at t1 = 30 (+/- 10 minutes) after t0, t2=1 (+/-15 minutes) hour after t0, t4 = 3 (+/- 15 minutes) hours after t0 (if the patient is still in the ED/hospital).
* For each draw, a minimum volume (after processing) of approximately 2 mL of plasma should be obtained. The specimens will be processed, aliquoted, and retained in a -70 secured freezer.
Inclusion/Exclusion Criteria
Inclusion Criteria:
* Patient greater than 21 years of age
* Experiencing symptoms of possible ACS
* Willing and able to comply with all aspect of the protocol
Exclusion Criteria:
* Acute distress and/or requires immediate life-saving intervention
* CPR, external defibrillation or cardioversion within 24 hours of presentation
* Unable to provide or understand the informed consent
* STEMI leading to immediate reperfusion
* Transferred from another facility
* Trauma related injuries
* Pregnancy or breast feeding
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OBSERVATIONAL REGISTRY
Individuals presenting with signs and/or symptoms of Acute Coronary Syndrome at the Henry Ford Hospital Emergency Department (ED).
OBSERVATIONAL REGISTRY
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OBSERVATIONAL REGISTRY
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Experiencing symptoms of possible ACS
* Willing and able to comply with all aspect of the protocol
Exclusion Criteria
* CPR, external defibrillation or cardioversion within 24 hours of presentation
* Unable to provide or understand the informed consent
* STEMI leading to immediate reperfusion
* Transferred from another facility
* Trauma related injuries
* Pregnancy or breast feeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henry Ford Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Richard M Nowak
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Richard M Nowak, MD
Role: PRINCIPAL_INVESTIGATOR
Henry Ford Health System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henry Ford Health System
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HFHS: ED CARDS Registry
Identifier Type: REGISTRY
Identifier Source: secondary_id
HFHS: ED-CARDS ACS Registry
Identifier Type: -
Identifier Source: org_study_id